• Home
  • COVID Treatment Options

View Recording
PowerPoint
Upcoming Grail Events: 11/7/24 & 12/11/24

COVID Treatment Options

  • 02/17/2022
  • 7:00 AM - 8:00 AM
  • Zoom

Registration


Registration is closed

COVID-19.  A word that has become part of our daily vocabulary.  With the ever-changing landscape, join us to learn the most current information here in Nebraska from a Nebraska physician.


Infectious disease specialist Jim Nora, MD, will present the various treatments options available for patients presenting with COVID-19.

NMA members are encouraged to join the discussion on what is, and what is not, working around the state. 

Educational Objectives
1) Review current testing options for COVID-19.
2) Review current outpatient treatment options for COVID-19.
3) Review current recommendations for vaccination.

1.0 CME Available

Policies and standards of the Nebraska Medical Education Trust require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity. The speaker and planning committee have no relevant financial relationships to disclose.

Nebraska Medical Education Trust designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nebraska Medical Education Trust is accredited by the Nebraska Medical Association to provide continuing medical education for physicians.

View the Recording (Expires 2/17/25)
Presentation
Post-test

Additional publication resources:
https://grail.com/manuscripts/

1. Validation for current Galleri assay: Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (All of our sensitivity, specificity test performance metrics are from this study)

2. Implementation study: Blood-based tests for multi cancer early detection (PATHFINDER): a prospective cohort study (Our 43% positive predictive value comes from this study)

3. Case series publication (Three stage 1 diagnoses): A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening.

Powered by Wild Apricot Membership Software